EP0463877A1 - Préparation pharmaceutique à libération contrôlée - Google Patents
Préparation pharmaceutique à libération contrôlée Download PDFInfo
- Publication number
- EP0463877A1 EP0463877A1 EP91305834A EP91305834A EP0463877A1 EP 0463877 A1 EP0463877 A1 EP 0463877A1 EP 91305834 A EP91305834 A EP 91305834A EP 91305834 A EP91305834 A EP 91305834A EP 0463877 A1 EP0463877 A1 EP 0463877A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- water
- pharmaceutical preparation
- coating layer
- controlled release
- acrylic polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Definitions
- the present invention relates to a controlled release pharmaceutical preparation, and more particularly to a so-called sigmoid type controlled release pharmaceutical preparation (Sigmoidal-Releasing System) from which a medicinal compound rapidly dissolves after a certain lag time.
- sigmoid type controlled release pharmaceutical preparation Sigmoidal-Releasing System
- a sustained release pharmaceutical preparation in which a core is alterately coated with two compositions, namely, with a coating composition comprising a water-soluble polymer such as a polyvinyl alcohol or polyvinylpyrrolidone and a water-insoluble polymer such as ethylcellulose, polyvinyl chloride or Eudragit RS (trade mark, from Röhm Pharma, Germany), and a composition comprising diltiazem hydrochloride, an organic acid and a lubricant to form multi coating layers.
- a coating composition comprising a water-soluble polymer such as a polyvinyl alcohol or polyvinylpyrrolidone and a water-insoluble polymer such as ethylcellulose, polyvinyl chloride or Eudragit RS (trade mark, from Röhm Pharma, Germany), and a composition comprising diltiazem hydrochloride, an organic acid and a lubricant to form multi coating layers.
- a sustained release pharmaceutical preparation (see japanese Unexamined Patent Publication No. 193913/1985) in which a core containing a medicinal active ingredient and an organic acid is spray-coated with an ethanol solution of an acrylic polymer having trimethylammoniumethyl group.
- An object of this invention is to provide a controlled release pharmaceutical preparation giving a so-called sigmoid type dissolution pattern wherein a lag time until the starting of the dissolution of a medicinal compound and the rate of the following dissolution can be controlled and the rate of the dissolution of the medicinal compound does not depend on the pH of a medium for the dissolution.
- the present invention provides a controlled release pharmaceutical preparation comprising a core containing a medicinal compound and a coating layer containing a water-repellent salt and a water-insoluble and slightly water-permeable acrylic polymer having trimethylammoniumethyl group.
- Fig. 1 is a graph showing the result of the dissolution test with water as to various controlled release granules (a) to (e) obtained in Test Example 1 which differ from each other in the amount of coating layer.
- Fig. 2 is a graph showing the result of the dissolution test with water, first fluid and second fluid as to the controlled release granule (d) obtained in Test Example 1.
- Fig. 3 is a graph showing the change in blood concentration of a medicinal compound in case that the granule (d) was administered to dogs in Test Example 2.
- Fig. 4 is a graph showing the result of the dissolution test as to a capsule containing various controlled release granules obtained in Test Example 3 which differ from each other in the amount of the coating layer.
- the controlled release pharmaceutical preparation of the present invention comprises a core containing a medicinal compound and a coating layer containing a water-repellent salt and a water-insoluble and slightly water-permeable acrylic polymer having trimethylammoniumethyl group, which surrounds said core.
- a coating layer containing a water-repellent salt and a water-insoluble and slightly water-permeable acrylic polymer having trimethylammoniumethyl group, which surrounds said core.
- another coating layer of at least one material selected from the group consisting of ethylcellulose, hydroxypropylcellulose and a medicinal compound may be provided around said coating layer in the controlled release pharmaceutical preparation of the present invention.
- a polymer of acrylic acid, methyl acrylate, ethyl acrylate, methacrylic acid, methyl methacrylate, ethyl methacrylate or the like, which has trimethylammoniumethyl group in the molecule may be used as a water-insoluble and slightly water-permeable acrylic polymer constituting the coating layer.
- a copolymer of ethyl acrylate, methyl methacrylate and ⁇ -acryloyloxyethyltrimethylammonium chloride in which about 0.025 to about 0.033 mole of ⁇ -acryloyloxyethyltrimethylammonium chloride is contained per mole of the other neutral acrylic monomers is preferably used.
- Such copolymer is, for example, commercially available under trade mark "Eudragit RS" from Röhm Pharma, Germany or the like.
- the above-mentioned polymer may contain, for instance, a small quantity of a water-permeable polymer.
- a water-permeable polymer is, for example, commercially available under trade mark "Eudragit RL” from Röhm Pharma, Germany or the like.
- ethylcellulose or hydroxypropylcellulose which is a material of another coating layer provided around the coating layer of an acrylic polymer, for instance, ethylcellulose containing about 46.5 to about 51.0 % of ethoxy group, hydroxypropylcellulose containing about 53.4 to about 77.5 % of hydroxypropoxy group or the like can be suitably used.
- a water-repellent salt which constitute the coating layer with an acrylic polymer a salt of higher fatty acid and an alkaline earth metal is preferably used.
- the salts are calcium stearate, magnecium stearate and the like.
- the ratio of the above-mentioned acrylic polymer and the water-repellent salt in the coating layer it is adequate that about 0.5 to about 5 parts by weight, preferably about 1.5 to about 4.5 parts by weight and more preferably about 2 to about 4 parts by weight of the acrylic polymer is contained per part by weight of the water-repellent salt.
- the amount of the coating layer for the core is variable a little depending on the form or the size of the core. However, it is preferable that the amount of the coating layer to be used tends to increase a bit depending on the increase of the surface area per unit weight, that is, the decrease of the particle size of the core. For example, in case of spherical particles having mean particle size of about 500 to about 1000 ⁇ m, the amount of the coating layer is about 5 to about 80 %, preferably about 7 to about 50 %, in particular, preferably about 8 to about 30 %, based on the weight of the core.
- the form of the core to be coated is not particularly limited and various forms such as plain tablet, pill, granule and fine granule may be suitably used.
- the granulated cores having mean particle size of about 300 to about 5000 ⁇ m, in particular, about 500 to about 1500 ⁇ m may be preferably used.
- the medicinal compound to be contained in the core is not particularly limited.
- calcium antagonists such as diltiazem hydrochloride, verapamil hydrochloride, nicardipine, nitrendipine and nimodipine, antiasthmatic agents such as theophylline and trimetaquinol, water soluble vitamins, antibiotics, antimalignatumor agents, antipyretic analgesics, antihyperglycemic agents and the like may be used.
- additives such as an excipient, a binder, a lubricant, an aggregation-preventing agent and a solubilizer for a medicinal compound which are usually used in this field may be contained in the core.
- excipients are sugars such as sucrose, lactose, mannitol and glucose, starch, crystalline cellulose, calcium phosphate, calcium sulfate, calcium lactate and the like.
- carriers for regulating particle sizes are sucrose, lactose, starch, crystalline cellulose and the like.
- binders are polyvinylalcohol, polyacrylic acid, polymethacrylic acid, polyvinylpyrrolidone, glucose, sucrose, lactose, maltose, sorbitol, mannitol, hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, macrogols, arabic gum, gelatin, agar, starch and the like.
- lubricants are stearic acid, talc and the like.
- aggregation-preventing agents are the above-mentioned lubricants, silicone dioxide, colloidal silicone dioxide and the like.
- solubilizers for medicinal compounds are organic acids such as fumaric acid, succinic acid and malic acid and the like.
- the pharmaceutical preparation of the present invention can be prepared by coating cores containing a medicinal compound with a dispersion of a water-insoluble and slightly water-permeable acrylic polymer having trimethylammoniumethyl group and a water-repellent salt.
- the preparation of the cores can be carried out according to the usual procedure for the preparation, for example, as described in Lemingtons Pharmaceutical Sciences 17 , 1603-1632, 1633-1643 (Mack Publishing Company, published in 1985).
- the cores can be prepared by granulating the composition of a medicinal compound, a binder and, as occasion demands, other additives such as an exicipent according to the method of wet oscillating granulation, rotating granulation, fluidizing bed granulation or the like to obtain granules.
- the cores may be prepared using carriers for regulating particle sizes. That is, spherically granulated carriers may be coated with a medicinal compound according to the usual method such as powder coating method to obtain the cores. Powder coating can be carried out, for instance, by gradually adding a medicinal compound or a mixture of the medicinal compound and suitable additives such as an excipient with spraying a solution obtained by dissolving a binder in a suitable solvent such as water, a lower alcohol such as methanol, ethanol, propanol, isopropanol or butanol, a lower alkanone such as acetone or methylethylketone, chloroform, dichloromethane, dichloroethane or a mixture thereof, on carrier particles to be cores, according to the method of rotating granulation, pan coating, fluidizing bed coating or the like.
- suitable solvent such as water, a lower alcohol such as methanol, ethanol, propanol, isopropanol or butanol, a lower al
- the coating for thus obtained cores can be carried out by adhering a dispersion of a water-repellent salt and an acrylic polymer to the cores followed by drying.
- a dispersion medium for the above-mentioned component of the coating layer water, an alcohol such as methanol, ethanol or propanol, a ketone such as acetone, a halogenated hydrocarbon such as methylenechloride or chloroform, a mixture thereof or the like is exemplified.
- Water, an alcohol or a mixture thereof is preferable, and ethanol or a mixture of ethanol and water is particularly preferable.
- the coating can be carried out according to a method generally used in the art for preparation such as the method of fluidizing bed coating or pan coating.
- the coating can be carried out as follows. That is, while the cores are fluidized in an apparatus by means of air pressure, they are spray-coated with an aqueous dispersion of a water-repellent salt and an acrylic acid polymer at an adequate rate from the nozzle of the spray-gun.
- the concentration of a water-repellent salt and an acrylic polymer in the dispersion is not particularly limited, but it is preferable that these components are added within the above-mentioned scope of the preferable proportion of both components, to be the concentration of about 5 to about 40 % by weight.
- a plasticizer, a coloring agent and the like may be contained in the dispersion.
- a plasticizer for instance, triacetin, triethyl citrate, acetyltributyl citrate, diethyl phthalate, polyethyleneglycol, polysorbate or the like can be suitably used.
- the amount of the plasticizer to be used is preferably about 5 to about 40 % by weight based on the weight of an acrylic polymer.
- the drying of thus obtained coating layer can be easily carried out, for example, by heating at about 35 to about 100°C, particularly about 40 to about 70°C.
- the other form of the pharmaceutical preparation of the present invention wherein another coating layer made of at least one material selected from the group consisting of ethylcellulose, hydroxypropylcellulose and a medicinal compound is provided around the coating layer containing a water-repellent salt and a water-insoluble and slightly water-permeable acrylic polymer having trimethylammoniumethyl group, can be easily prepared by further coating the above-mentioned pharmaceutical preparation having the coating layer of an acrylic polymer with these components according to the usual method.
- the solution prepared by dissolving ethylcellulose or hydroxypropylcellulose in water, methanol, ethanol, acetone or a mixed solvent thereof to be the concentration of about 0.5 to about 10 % may be sprayed for coating.
- the solution or dispersion containing said medicinal compound or a mixture of the medicinal compound and suitable additives such as an excipient and a binder may be sprayed for coating according to the usual method.
- the additives for instance, the above-mentioned binders and excipients may be suitably used.
- controlled release pharmaceutical preparation of the present invention may be administered as it is or in a form filled in capsules.
- the pharmaceutical preparation of the present invention has the following characteristics because of its coating layer of a slightly water-permeable acrylic polymer. That is, a medicinal active ingredient rapidly dissolves from the preparation after a certain period which depends upon the amount of the coating layer although it never dissolves after administration until the certain time passes. Besides, the time until the start of the dissolution of a medicinal active ingredient is optionally adjustable by changing the amount of the coating layer.
- the pharmaceutical preparation of the present invention is useful as a pharmaceutical preparation wherein the starting of the dissolution of a pharmaceutical compound can be adjusted by itself. And it is further useful that the pharmaceutical preparation which can retain an effective blood concentration for many hours can be obtained by combining various pharmaceutical preparations which differ from each other in the amount of the coating layer or in a kind of a component of the coating layer, according to the present invention.
- the pharmaceutical preparation of the present invention wherein the coating layer of a slightly water-permeable acrylic polymer is futher coated with ethylcellulose, hydroxypropylcellulose or the like has a following advantage. That is, because the dissolution rate of a medicinal compound after a lag time in such pharmaceutical preparation is smaller than that in a pharmaceutical preparation whose coating layer of an acrylic polymer and a water-repellent salt is not further coated, the most suitable dissolution pattern can be obtained by employing the above-mentioned coating layer in accordance with a kind of medicinal active ingredient.
- these pharmaceutical preparations also have an advantage of being useful for preventing the aggregation of the preparations, which occurs during preparing them.
- the pharmaceutical preparation wherein the layer of a medicinal compound is provided around the coating layer of an acrylic polymer can start the dissolution of the inside medicinal compound when the blood concentration originated in the outside medicinal compound has lowered after its dissolution followed by the rise of its concentration, by adjusting the amounts of the medicinal compound layer and an acrylic polymer layer or providing another coating layer of hydroxypropylcellulose or the like around the layer of a medicinal compound. Therefore, the pharmaceutical preparation of the present invention has an advantage that it can be administered as a pharmaceutical preparation suitable for administration a day.
- Nonpareil granulated sucrose, from Freund Industrial Co. Ltd., Japan having the diameter of 350 to 500 ⁇ m (80 g) was put into the centrifugal fluidizing type granulating and coating apparatus (CF-360EX Type, made by Freund Industrial Co. Ltd., Japan) and rolled in it.
- CF-360EX Type centrifugal fluidizing type granulating and coating apparatus
- this plain granule was spray-coated with a solution containing 30 parts of Eudragit RS, 10 parts of calcium stearate and 3 parts of triethyl citrate to obtain various controlled release pharmaceutical preparations (a) to (e) containing diltiazem hydrochloride, which differ from each other in the amount of the coating layer on the plain granule as shown in Table 1.
- Plain granule containing diltiazem hydrochloride which was not yet coated was used as a control preparation.
- Fig. 1 The result of the dissolution test in 1 is shown in Fig. 1. It is recognized that according to the pharmaceutical preparation of the present invention, the medicinal compounds are completely released and their dissolution patterns show sigmoid type in water, although the lag time until the start of the dissolution is prolonged according as the increase of the amount of the coating layer in the pharmaceutical preparation.
- a medicinal compound dissolves immediately after a lag time irrespective of the pH change in the digestive tract.
- the controlled release pharmaceutical preparation (d) obtained in Test Example 1 was orally administered (dose: 100 mg as the amount of diltiazem hydrochloride) to dogs. After administration the blood was collected from vein at fixed times. The plasma concentration of diltiazem hydrochloride was measured by high performance liquid chromatography.
- the controlled release pharmaceutical preparations (a) (373 g) and (d) (800 g) obtained in the Test Example 1 and the plain granule (111 g) containing diltiazem hydrochloride were mixed.
- the mixture ( 128 mg) containing 100 mg of diltiazem hydrochloride was filled into a gelatin capsule to obtain a controlled release capsule.
- Nonpareil 103 (granulated sucrose, from Freund Industrial Co. Ltd., Japan) which was a spherically granulated sucrose having the diameter of 350 to 500 ⁇ m (800 g) was put into the centrifugal fluidizing type granulating and coating apparatus (made by Freund Industrial Co. Ltd., Japan hereinafter referred to as CF apparatus) and rolled in it. Thereto was gradually spread fine powder of diltiazem hydrochloride (9 kg) with spraying a solution of polyvinylpyrrolidone (200 g) in a mixture of ethanol and water ( 2 : 3 ) ( 6. 4 kg).
- Example 2 The procedure was carried out in the same manner as in Example 1 except that a mixture of Eudragit RS (112 g), calcium stearate (37 g), triethyl citrate (11 g), ethanol (210 g) and water (430 g) was used as a coating solution to obtain a controlled release pharmaceutical preparation containing diltiazem hydrochloride (yield: 1.16 kg).
- Example 2 The procedure was carried out in the same manner as in Example 1 except that a mixture of Eudragit RS (140 g), calcium stearate (47 g), triethyl citrate (14 g), ethanol (267 g) and water (533 g) was used as a coating solution to obtain a controlled release pharmaceutical preparation containing diltiazem hydrochloride (yield: 1.2 kg).
- Example 3 The procedure was carried out in the same manner as in Example 3 except that magnesium stearate (47 g) was used instead of calcium stearate to obtain a controlled release pharmaceutical preparation containing diltiazem hydrochloride (yield: 1.2 kg).
- the controlled release pharmaceutical preparation (0.56 kg) containing diltiazem hydrochloride obtained in the same manner as in Example 3 was put into CF apparatus and spray-coated with a coating solution consisting of ethylcellulose (9.5 g), hydroxypropylcellulose (0.5 g), ethanol (59 g) and water (32 g). Then the preparation was dried at 60°C for 16 hours to obtain a controlled release pharmaceutical preparation containing diltiazem hydrochloride (yield: 0.57 kg).
- the controlled release pharmaceutical preparation (1.12 kg) containing diltiazem hydrochloride obtained in the same manner as in Example 3 was put into CF apparatus and spray-coated with a coating solution consisting of diltiazem hydrochloride (151 g), polyvinylpyrrolidone (12 g), ethanol (87 g) and water (203 g). Then the preparation was dried at 60°C for 16 hows to obtain a controlled release pharmaceutical preparation containing diltiazem hydrochloride, wherein the part which rapidly released diltiazem hydrochloride was provided in its surface layer.
- Nonpareil 103 which was a spherically granulated sucrose having the diameter of 350 to 500 ⁇ m (1500 g) was put into CF apparatus and rolled in it. Thereto was gradually spread fine powder of nicotinamide (NA) (900 g) with spraying a solution of sucrose (135 g) in a mixture (465 g) of ethanol and water (1:3). The plain granule having the diameter of 12 to 20 mesh (1400 to 840 ⁇ m) containing NA, wherein Nonpareil was coated around its surface with NA, was thus prepared.
- NA nicotinamide
- the obtained plain granule (0.5 kg) containing NA was put into CF apparatus and spray-coated with a solution consisiting of Eudragit RS (105 g), calcium stearate (35 g), triethyl citrate (11 g), ethanol (200 g) and water (400 g). Then the granule was dried by heating at 60°C for 16 hours to obtain a controlled release pharmaceutical preparation containing NA (yield: 0.56 kg).
- Nonpareil 103 which was a spherically granulated sucrose having the diameter of 500 to 710 ⁇ m (1.04 kg) was put into CF apparatus and rolled in it. Thereto was gradually spread a mixed powder of fine powder of (+)-( 2S, 3S)-3-acetoxy-8-chloro-5-[2-(dimethylamino)ethyl]-2, 3-dihydro-2-(4-methoxyphenyl)- 1,5-benzothiazepin-4(5H)-one ⁇ maleate (hereinafter referred to as Clentiazem) (1.176 kg) and succinic acid (1.96 kg) with spraying a solution of sucrose (0.78 kg) in the mixture of ethanol and water (1 : 3) (2.22 kg).
- Clentiazem (1.176 kg
- succinic acid (1.96 kg
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Surgical Instruments (AREA)
- Stringed Musical Instruments (AREA)
- Pens And Brushes (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP171762/90 | 1990-06-28 | ||
JP17176290 | 1990-06-28 | ||
SG4995A SG4995G (en) | 1990-06-28 | 1995-01-13 | Controlled release pharmaceutical preparation |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0463877A1 true EP0463877A1 (fr) | 1992-01-02 |
EP0463877B1 EP0463877B1 (fr) | 1994-06-01 |
EP0463877B2 EP0463877B2 (fr) | 1997-07-02 |
Family
ID=26494375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP91305834A Expired - Lifetime EP0463877B2 (fr) | 1990-06-28 | 1991-06-27 | Préparation pharmaceutique à libération contrÔlée |
Country Status (17)
Country | Link |
---|---|
US (1) | US5137733A (fr) |
EP (1) | EP0463877B2 (fr) |
JP (1) | JP2558396B2 (fr) |
KR (1) | KR0133511B1 (fr) |
CN (1) | CN1040061C (fr) |
AT (1) | ATE106241T1 (fr) |
CA (1) | CA2045358C (fr) |
DE (1) | DE69102211T3 (fr) |
DK (1) | DK0463877T3 (fr) |
ES (1) | ES2055962T5 (fr) |
FI (1) | FI103476B (fr) |
GR (1) | GR3024471T3 (fr) |
HK (1) | HK33895A (fr) |
HU (1) | HU214590B (fr) |
IE (1) | IE64629B1 (fr) |
IL (1) | IL98611A (fr) |
SG (1) | SG4995G (fr) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0553392A1 (fr) * | 1992-01-27 | 1993-08-04 | Euro-Celtique S.A. | Formulations stabilisées à libération contrôlée enrobées d'une couche de polymère acrylique |
EP0636366A2 (fr) * | 1993-07-27 | 1995-02-01 | Euroceltique S.A. | Formulations à libérations contrôlée enrobée d'une dispersion aqueuse de polymères acryliques |
US5830503A (en) * | 1996-06-21 | 1998-11-03 | Andrx Pharmaceuticals, Inc. | Enteric coated diltiazem once-a-day formulation |
US5834023A (en) * | 1995-03-24 | 1998-11-10 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation |
WO1999059557A1 (fr) * | 1998-05-20 | 1999-11-25 | Laboratoires Prographarm | Forme pharmaceutique multiparticulaire a liberation programmee et pulsee et son procede de preparation |
US6039979A (en) * | 1999-01-13 | 2000-03-21 | Laboratoires Prographarm | Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation |
WO2000042998A1 (fr) * | 1999-01-21 | 2000-07-27 | Elan Corporation, Plc | Formulation de bisoprolol multiparticulaire |
US6129933A (en) * | 1991-12-24 | 2000-10-10 | Purdue Pharma Lp | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
WO2001047500A1 (fr) * | 1999-12-23 | 2001-07-05 | Pfizer Products Inc. | Forme de dosage de medicament entraine par un hydrogel |
US6306438B1 (en) | 1997-07-02 | 2001-10-23 | Euro-Celtique, S.A. | Stabilized sustained release tramadol formulations |
WO2002028376A3 (fr) * | 2000-10-03 | 2003-03-06 | Mehta Atul M | Preparations a chrono-administration et methode d'utilisation |
WO2003041696A1 (fr) * | 2001-11-15 | 2003-05-22 | Athpharma | Procedes et compositions d'utilisation de (s)-bisoprolol |
US6733789B1 (en) | 1999-01-21 | 2004-05-11 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
EP1419766A1 (fr) * | 1993-06-23 | 2004-05-19 | Euro-Celtique S.A. | Formulations à libération controlée enrobées avec dispersions aqueuses d'éthylcellulose |
US6984402B2 (en) | 2000-10-03 | 2006-01-10 | Elite Laboratories, Inc. | Chrono delivery formulations and method of treating atrial fibrillation |
US7070806B2 (en) | 1992-01-27 | 2006-07-04 | Purdue Pharma Lp | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US8026286B2 (en) | 1999-12-23 | 2011-09-27 | Bend Research, Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
EP2386295A2 (fr) | 2004-09-10 | 2011-11-16 | Jagotec Ag | Comprimes a liberation gastro-intestinale du principe actif regulee en foction du temps et du site |
US8168218B2 (en) | 2003-04-24 | 2012-05-01 | Jagotec Ag | Delayed release tablet with defined core geometry |
US9974752B2 (en) | 2014-10-31 | 2018-05-22 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1053808C (zh) * | 1993-04-24 | 2000-06-28 | 章修纲 | 尼非地平控释剂型 |
JP2916978B2 (ja) * | 1993-08-25 | 1999-07-05 | エスエス製薬株式会社 | 放出開始制御型製剤 |
US5834024A (en) | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
US6486177B2 (en) * | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US5922736A (en) * | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
US6962997B1 (en) * | 1997-05-22 | 2005-11-08 | Celgene Corporation | Process and intermediates for resolving piperidyl acetamide steroisomers |
KR20010040819A (ko) | 1998-02-10 | 2001-05-15 | 가마꾸라 아끼오 | 제어방출형 제제 |
US6524620B2 (en) | 1998-07-20 | 2003-02-25 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation and method of manufacture |
DE19845358A1 (de) * | 1998-10-02 | 2000-04-06 | Roehm Gmbh | Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe |
US20010055613A1 (en) | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
US6270805B1 (en) | 1998-11-06 | 2001-08-07 | Andrx Pharmaceuticals, Inc. | Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate |
US20040185099A1 (en) * | 2000-01-20 | 2004-09-23 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
US6635277B2 (en) | 2000-04-12 | 2003-10-21 | Wockhardt Limited | Composition for pulsatile delivery of diltiazem and process of manufacture |
SE0100200D0 (sv) | 2001-01-24 | 2001-01-24 | Astrazeneca Ab | New film coating |
AU2002339378A1 (en) * | 2001-05-22 | 2002-12-03 | Euro-Celtique | Compartmentalized dosage form |
US9358214B2 (en) | 2001-10-04 | 2016-06-07 | Adare Pharmaceuticals, Inc. | Timed, sustained release systems for propranolol |
US20030118652A1 (en) * | 2001-11-15 | 2003-06-26 | John Kelly | Methods and compositions for use of (S)-bisoprolol |
US20050025824A1 (en) * | 2001-12-14 | 2005-02-03 | Eurand Pharmaceuticals Ltd. | Pulsatile release histamine H2 antagonist dosage form |
US6663888B2 (en) * | 2001-12-14 | 2003-12-16 | Eurand Pharmaceuticals Ltd. | Pulsatile release histamine H2 antagonist dosage form |
US8367111B2 (en) * | 2002-12-31 | 2013-02-05 | Aptalis Pharmatech, Inc. | Extended release dosage forms of propranolol hydrochloride |
CA2518806C (fr) * | 2003-03-11 | 2012-05-01 | Seikagaku Corporation | Composition polysaccharide photoreticulee et procede de fabrication |
FR2861990B1 (fr) * | 2003-11-10 | 2006-02-10 | Nouveaux Produits Pharma | Comprimes faiblement doses a reseau de polymeres |
US20050239830A1 (en) * | 2004-04-26 | 2005-10-27 | Vikram Khetani | Methods of diminishing co-abuse potential |
US20080249062A1 (en) * | 2004-05-07 | 2008-10-09 | Katsuya Takahashi | Nucleus Pulposus Filler |
US8747895B2 (en) | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
NZ728442A (en) | 2004-10-21 | 2018-05-25 | Adare Pharmaceuticals Inc | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
EP1830648A4 (fr) * | 2004-12-09 | 2008-03-12 | Celgene Corp | Traitement au moyen de d-threo methylphenidate |
US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
US8846100B2 (en) * | 2006-05-12 | 2014-09-30 | Shire Llc | Controlled dose drug delivery system |
SI2049123T2 (sl) | 2006-08-03 | 2016-10-28 | Horizon Pharma Ag | Zdravljenje revmatoznih bolezni z zadržanim sproščanjem glukokortikoida |
JP2008024708A (ja) * | 2007-08-20 | 2008-02-07 | Euro-Celtique Sa | アクリル系ポリマーの水性分散液で被膜した放出制御型製剤及びその方法 |
PT2358360T (pt) * | 2008-11-18 | 2016-11-15 | Ucb Biopharma Sprl | Formulações de libertação prolongada compreendendo um derivado de 2-oxo-1-pirrolidina |
BRPI1001091A2 (pt) * | 2009-04-22 | 2011-03-22 | Dr Suwelack Skin & Health Care Ag | artigo moldado revestido secado por congelamento |
MX2012006240A (es) | 2009-12-02 | 2012-10-03 | Aptalis Pharma Ltd | Microcapsulas de fexofenadina y composiciones que contienen las mismas. |
KR20140056136A (ko) * | 2010-12-03 | 2014-05-09 | 닛뽕소다 가부시키가이샤 | 하이드록시알킬셀룰로오스 |
US9498447B2 (en) | 2011-03-23 | 2016-11-22 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9283214B2 (en) | 2011-03-23 | 2016-03-15 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9119809B2 (en) | 2011-03-23 | 2015-09-01 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US9603809B2 (en) | 2011-03-23 | 2017-03-28 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
US8927010B2 (en) | 2011-03-23 | 2015-01-06 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US11241391B2 (en) | 2011-03-23 | 2022-02-08 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US10905652B2 (en) | 2011-03-23 | 2021-02-02 | Ironshore Pharmaceuticals & Development, Inc. | Compositions for treatment of attention deficit hyperactivity disorder |
US8916588B2 (en) | 2011-03-23 | 2014-12-23 | Ironshore Pharmaceuticals & Development, Inc. | Methods for treatment of attention deficit hyperactivity disorder |
DK2688557T3 (da) | 2011-03-23 | 2017-11-27 | Ironshore Pharmaceuticals & Dev Inc | Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed |
US10292937B2 (en) | 2011-03-23 | 2019-05-21 | Ironshore Pharmaceuticals & Development, Inc. | Methods of treatment of attention deficit hyperactivity disorder |
JP5146859B2 (ja) * | 2011-07-11 | 2013-02-20 | ユーロ−セルティーク エス.エイ. | アクリル系ポリマーの水性分散液で被膜した放出制御型製剤及びその方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0315414A1 (fr) * | 1987-11-06 | 1989-05-10 | Tanabe Seiyaku Co., Ltd. | Dispositif pharmaceutique à libération contrôlée |
EP0386440A1 (fr) * | 1989-02-11 | 1990-09-12 | Bayer Ag | Médicament à libération contrôlée |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5944311A (ja) * | 1982-09-07 | 1984-03-12 | Santen Pharmaceut Co Ltd | 徐放性顆粒およびその製造法 |
US5002776A (en) * | 1983-12-22 | 1991-03-26 | Elan Corporation, Plc | Controlled absorption diltiazem formulations |
IE56999B1 (en) * | 1983-12-22 | 1992-03-11 | Elan Corp Plc | Pharmaceutical formulation |
US4559225A (en) * | 1984-02-16 | 1985-12-17 | Fourman Robert G | Sunscreen composition |
JPH0621066B2 (ja) * | 1984-03-14 | 1994-03-23 | 杏林製薬株式会社 | 3―イソブチリル―2―イソプロピルピラゾロ〔1,5―a〕ピリジンの徐放性医薬品組成物 |
GB8518301D0 (en) * | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
GB8707416D0 (en) * | 1987-03-27 | 1987-04-29 | Wellcome Found | Pharmaceutical formulations |
US4983401A (en) * | 1989-05-22 | 1991-01-08 | Kinaform Technology, Inc. | Sustained release pharmaceutical preparations having pH controlled membrane coatings |
US5013557A (en) * | 1989-10-03 | 1991-05-07 | Warner-Lambert Company | Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same |
JPH0674206B2 (ja) * | 1989-12-28 | 1994-09-21 | 田辺製薬株式会社 | 放出制御型製剤およびその製法 |
-
1991
- 1991-06-11 JP JP3138998A patent/JP2558396B2/ja not_active Expired - Lifetime
- 1991-06-18 FI FI912952A patent/FI103476B/fi not_active IP Right Cessation
- 1991-06-21 IE IE216691A patent/IE64629B1/en not_active IP Right Cessation
- 1991-06-25 IL IL9861191A patent/IL98611A/en not_active IP Right Cessation
- 1991-06-25 CA CA002045358A patent/CA2045358C/fr not_active Expired - Lifetime
- 1991-06-27 DE DE69102211T patent/DE69102211T3/de not_active Expired - Lifetime
- 1991-06-27 EP EP91305834A patent/EP0463877B2/fr not_active Expired - Lifetime
- 1991-06-27 AT AT91305834T patent/ATE106241T1/de not_active IP Right Cessation
- 1991-06-27 DK DK91305834.3T patent/DK0463877T3/da active
- 1991-06-27 HU HU912170A patent/HU214590B/hu unknown
- 1991-06-27 ES ES91305834T patent/ES2055962T5/es not_active Expired - Lifetime
- 1991-06-28 CN CN91105399A patent/CN1040061C/zh not_active Expired - Lifetime
- 1991-06-28 KR KR1019910010955A patent/KR0133511B1/ko not_active IP Right Cessation
- 1991-06-28 US US07/723,031 patent/US5137733A/en not_active Expired - Lifetime
-
1995
- 1995-01-13 SG SG4995A patent/SG4995G/en unknown
- 1995-03-09 HK HK33895A patent/HK33895A/xx not_active IP Right Cessation
-
1997
- 1997-08-14 GR GR970402109T patent/GR3024471T3/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0315414A1 (fr) * | 1987-11-06 | 1989-05-10 | Tanabe Seiyaku Co., Ltd. | Dispositif pharmaceutique à libération contrôlée |
EP0386440A1 (fr) * | 1989-02-11 | 1990-09-12 | Bayer Ag | Médicament à libération contrôlée |
Cited By (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6129933A (en) * | 1991-12-24 | 2000-10-10 | Purdue Pharma Lp | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US7316821B2 (en) | 1991-12-24 | 2008-01-08 | Purdue Pharma, L.P. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US6905709B2 (en) | 1991-12-24 | 2005-06-14 | Purdue Pharma, Lp | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
US7070806B2 (en) | 1992-01-27 | 2006-07-04 | Purdue Pharma Lp | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
EP0553392A1 (fr) * | 1992-01-27 | 1993-08-04 | Euro-Celtique S.A. | Formulations stabilisées à libération contrôlée enrobées d'une couche de polymère acrylique |
US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5639476A (en) * | 1992-01-27 | 1997-06-17 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US6143353A (en) * | 1992-01-27 | 2000-11-07 | Purdue Pharma Lp | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
EP1419766A1 (fr) * | 1993-06-23 | 2004-05-19 | Euro-Celtique S.A. | Formulations à libération controlée enrobées avec dispersions aqueuses d'éthylcellulose |
EP0636366A3 (fr) * | 1993-07-27 | 1998-02-04 | Euroceltique S.A. | Formulations à libérations contrôlée enrobée d'une dispersion aqueuse de polymères acryliques |
EP0636366A2 (fr) * | 1993-07-27 | 1995-02-01 | Euroceltique S.A. | Formulations à libérations contrôlée enrobée d'une dispersion aqueuse de polymères acryliques |
US5834023A (en) * | 1995-03-24 | 1998-11-10 | Andrx Pharmaceuticals, Inc. | Diltiazem controlled release formulation |
US5830503A (en) * | 1996-06-21 | 1998-11-03 | Andrx Pharmaceuticals, Inc. | Enteric coated diltiazem once-a-day formulation |
US6306438B1 (en) | 1997-07-02 | 2001-10-23 | Euro-Celtique, S.A. | Stabilized sustained release tramadol formulations |
US6645527B2 (en) | 1997-07-02 | 2003-11-11 | Euro-Celtique S.A. | Stabilized sustained release tramadol formulations |
FR2778848A1 (fr) * | 1998-05-20 | 1999-11-26 | Prographarm Lab | Forme pharmaceutique multiparticulaire a liberation programmee et pulsee et son procede de preparation |
WO1999059557A1 (fr) * | 1998-05-20 | 1999-11-25 | Laboratoires Prographarm | Forme pharmaceutique multiparticulaire a liberation programmee et pulsee et son procede de preparation |
US6039979A (en) * | 1999-01-13 | 2000-03-21 | Laboratoires Prographarm | Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation |
WO2000042998A1 (fr) * | 1999-01-21 | 2000-07-27 | Elan Corporation, Plc | Formulation de bisoprolol multiparticulaire |
US6733789B1 (en) | 1999-01-21 | 2004-05-11 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
WO2001047500A1 (fr) * | 1999-12-23 | 2001-07-05 | Pfizer Products Inc. | Forme de dosage de medicament entraine par un hydrogel |
US8026286B2 (en) | 1999-12-23 | 2011-09-27 | Bend Research, Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
EP1967185A1 (fr) * | 1999-12-23 | 2008-09-10 | Pfizer Products Inc. | Forme de dosage de médicament entraîné par un hydrogél |
WO2002028376A3 (fr) * | 2000-10-03 | 2003-03-06 | Mehta Atul M | Preparations a chrono-administration et methode d'utilisation |
US6984402B2 (en) | 2000-10-03 | 2006-01-10 | Elite Laboratories, Inc. | Chrono delivery formulations and method of treating atrial fibrillation |
WO2003041696A1 (fr) * | 2001-11-15 | 2003-05-22 | Athpharma | Procedes et compositions d'utilisation de (s)-bisoprolol |
US9040085B2 (en) | 2003-04-24 | 2015-05-26 | Jagotec Ag | Delayed release tablet with defined core geometry |
US8168218B2 (en) | 2003-04-24 | 2012-05-01 | Jagotec Ag | Delayed release tablet with defined core geometry |
US8309124B2 (en) | 2003-04-24 | 2012-11-13 | Jagotec Ag | Delayed release tablet with defined core geometry |
US8394407B2 (en) | 2003-04-24 | 2013-03-12 | Jagotec Ag | Delayed release tablet with defined core geometry |
US9186332B2 (en) | 2003-04-24 | 2015-11-17 | Jagotec Ag | Delayed release tablet with defined core geometry |
US9884021B2 (en) | 2003-04-24 | 2018-02-06 | Jagotec Ag | Delayed release tablet with defined core geometry |
EP2386295A2 (fr) | 2004-09-10 | 2011-11-16 | Jagotec Ag | Comprimes a liberation gastro-intestinale du principe actif regulee en foction du temps et du site |
US10292939B2 (en) | 2014-10-31 | 2019-05-21 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10111839B2 (en) | 2014-10-31 | 2018-10-30 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US9974752B2 (en) | 2014-10-31 | 2018-05-22 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
US10292938B2 (en) | 2014-10-31 | 2019-05-21 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10449159B2 (en) | 2014-10-31 | 2019-10-22 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10500162B2 (en) | 2014-10-31 | 2019-12-10 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10507186B2 (en) | 2014-10-31 | 2019-12-17 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10512612B2 (en) | 2014-10-31 | 2019-12-24 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10512613B2 (en) | 2014-10-31 | 2019-12-24 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10568841B2 (en) | 2014-10-31 | 2020-02-25 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10688060B2 (en) | 2014-10-31 | 2020-06-23 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US11896722B2 (en) | 2014-10-31 | 2024-02-13 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Also Published As
Publication number | Publication date |
---|---|
HUT59321A (en) | 1992-05-28 |
DE69102211T3 (de) | 1997-08-28 |
IE64629B1 (en) | 1995-08-23 |
FI103476B1 (fi) | 1999-07-15 |
IE912166A1 (en) | 1992-01-01 |
EP0463877B2 (fr) | 1997-07-02 |
SG4995G (en) | 1995-06-16 |
IL98611A0 (en) | 1992-07-15 |
DK0463877T3 (da) | 1994-06-27 |
CN1040061C (zh) | 1998-10-07 |
AU7924391A (en) | 1992-01-02 |
ATE106241T1 (de) | 1994-06-15 |
US5137733A (en) | 1992-08-11 |
FI103476B (fi) | 1999-07-15 |
GR3024471T3 (en) | 1997-11-28 |
IL98611A (en) | 1998-10-30 |
ES2055962T5 (es) | 1997-09-16 |
HU912170D0 (en) | 1991-12-30 |
JP2558396B2 (ja) | 1996-11-27 |
DE69102211D1 (de) | 1994-07-07 |
ES2055962T3 (es) | 1994-09-01 |
JPH04235123A (ja) | 1992-08-24 |
AU634400B2 (en) | 1993-02-18 |
CA2045358A1 (fr) | 1991-12-29 |
HU214590B (hu) | 1998-04-28 |
FI912952A0 (fi) | 1991-06-18 |
DE69102211T2 (de) | 1994-09-15 |
CA2045358C (fr) | 1998-04-28 |
KR920000313A (ko) | 1992-01-29 |
HK33895A (en) | 1995-03-17 |
KR0133511B1 (ko) | 1998-04-23 |
FI912952A (fi) | 1991-12-29 |
EP0463877B1 (fr) | 1994-06-01 |
CN1058533A (zh) | 1992-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0463877B1 (fr) | Préparation pharmaceutique à libération contrôlée | |
EP0253684B1 (fr) | Préparation à libération prolongée et sa fabrication | |
EP0640337B1 (fr) | Composition pharmaceutique avec commencement et vitesse contrôlés de la libération | |
EP1123700B1 (fr) | Système d'administration pulsatile des médicaments | |
EP0149920B1 (fr) | Formulation pharmaceutique | |
US5601845A (en) | Pharmaceutical spheroid formulation | |
EP0605174B1 (fr) | Préparation pharmaceutique à libération retardée et continue | |
FI103475B (fi) | Menetelmä kontrolloidusti vapauttavan valmisteen valmistamiseksi | |
CA1339078C (fr) | Preparation pharmaceutique a liberation-retard; methode de preparation | |
KR940002655B1 (ko) | 조절 방출성 용량 형태 | |
JP3426230B2 (ja) | 複数層の制御放出処方剤 | |
EP0142561A1 (fr) | Preparation a base de nifedipine a action prolongee | |
EP0386967B1 (fr) | Matériau d'enrobage contrôlant la libération d'un médicament pour des formulations à activité prolongée | |
JPH07552B2 (ja) | 持効性製剤 | |
US5258186A (en) | Drug release controlling coating material for long acting formulations | |
JPH04338323A (ja) | 放出制御製剤およびその製造法 | |
JPH10120571A (ja) | 塩酸ジルチアゼム徐放性製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T4 |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19920120 |
|
17Q | First examination report despatched |
Effective date: 19921120 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 106241 Country of ref document: AT Date of ref document: 19940615 Kind code of ref document: T |
|
ITF | It: translation for a ep patent filed |
Owner name: JACOBACCI CASETTA & PERANI S.P.A. |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
ET | Fr: translation filed | ||
REF | Corresponds to: |
Ref document number: 69102211 Country of ref document: DE Date of ref document: 19940707 |
|
EPTA | Lu: last paid annual fee | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2055962 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3012582 |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
EAL | Se: european patent in force in sweden |
Ref document number: 91305834.3 |
|
26 | Opposition filed |
Opponent name: ROEHM GMBH Effective date: 19941208 |
|
NLR1 | Nl: opposition has been filed with the epo |
Opponent name: ROHM GMBH |
|
PLAW | Interlocutory decision in opposition |
Free format text: ORIGINAL CODE: EPIDOS IDOP |
|
PLAW | Interlocutory decision in opposition |
Free format text: ORIGINAL CODE: EPIDOS IDOP |
|
PUAH | Patent maintained in amended form |
Free format text: ORIGINAL CODE: 0009272 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT MAINTAINED AS AMENDED |
|
27A | Patent maintained in amended form |
Effective date: 19970702 |
|
AK | Designated contracting states |
Kind code of ref document: B2 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T4 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: AEN Free format text: AUFRECHTERHALTUNG DES PATENTES IN GEAENDERTER FORM |
|
NLR2 | Nl: decision of opposition | ||
ET3 | Fr: translation filed ** decision concerning opposition | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: DC2A Kind code of ref document: T5 Effective date: 19970722 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3024471 |
|
NLR3 | Nl: receipt of modified translations in the netherlands language after an opposition procedure | ||
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20100709 Year of fee payment: 20 Ref country code: DK Payment date: 20100610 Year of fee payment: 20 Ref country code: LU Payment date: 20100616 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20100610 Year of fee payment: 20 Ref country code: IT Payment date: 20100622 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20100616 Year of fee payment: 20 Ref country code: ES Payment date: 20100630 Year of fee payment: 20 Ref country code: CH Payment date: 20100614 Year of fee payment: 20 Ref country code: BE Payment date: 20100518 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20100609 Year of fee payment: 20 Ref country code: DE Payment date: 20100625 Year of fee payment: 20 Ref country code: GB Payment date: 20100623 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20100519 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69102211 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69102211 Country of ref document: DE |
|
BE20 | Be: patent expired |
Owner name: *TANABE SEIYAKU CO. LTD Effective date: 20110627 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V4 Effective date: 20110627 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EUP |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20110626 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20110627 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20110626 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20120220 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20110628 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20110628 |